Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28351674 | 0.98 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL303434 | 0.98 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL4180063 | 0.96 | CTSK (0.43) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL3799622 | 0.91 | PLA2G10 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL27147241 | 0.91 | PLA2G10 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL3470166 | 0.91 | PLA2G10 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL10316747 | 0.87 | CTSK (0.38) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL4774700 | 0.87 | ALOX15 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL14312161 | 0.86 | SIGMAR1 (0.48) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL15199218 | 0.85 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116675731-A | Small molecule conjugate of targeted cyclin-dependent kinase 12/13 and application thereof | 浙江大学 | 2023-09-01 | — | — | CN | disclosed |
| WO-2019118612-A1 | TARGETING COMPOUNDS | ZAFGEN, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| CN-104395301-B | Bicyclic thiophene base amide compound | 霍夫曼-拉罗奇有限公司 | 2017-07-28 | — | — | CN | disclosed |
| US-20170183345-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-06-29 | — | — | US | disclosed |
| US-9550737-B2 | TNF -α modulating benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2017-01-24 | — | — | US | disclosed |
| EP-2594556-B1 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2594557-B1 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2015-06-04 | — | — | US | disclosed |
| EP-2858983-A1 | TNF -ALPHA MODULATING BENZIMIDAZOLES | UCB Biopharma SPRL (BE) | 2015-04-15 | — | — | EP | disclosed |
| US-8728707-B2 | Resist composition and method for producing resist pattern | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20130022909-A1 | RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-01-24 | — | — | US | disclosed |
| US-20130022909-A1 | RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-01-24 | — | — | US | disclosed |
| US-20120219899-A1 | RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120219899-A1 | RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| WO-2011123937-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-13 | — | — | WO | disclosed |
| WO-2009093009-A1 | FUSED TRICYCLIC THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-30 | — | — | WO | disclosed |
| EP-1757628-A1 | LACTONE COPOLYMER AND RADIATION-SENSITIVE RESIN COMPOSITION | JSR Corporation (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-0121244-B1 | CEPHALOSPORIN DERIVATIVES | Bristol-Myers Company (US) | 1990-09-12 | — | — | EP | disclosed |
| US-4525473-A | BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1985-06-25 | — | — | US | disclosed |
| EP-0121244-A2 | Cephalosporin derivatives | Bristol-Myers Company (US) | 1984-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | TNF, TNFRSF1A, NFKBIA | ALDH1A1 317/4885SMN1; SMN2 674/4885MEN1 3836/4885 |
| US-20170183345-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K6 | ALDH1A1 1830/4885SMN1; SMN2 4129/4885MEN1 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.